Genmab Details February Transactions Under DKK 725 Million Share Buy-back Program

The latest update is out from Genmab ( (GMAB) ).

Genmab A/S, the Copenhagen-headquartered biotechnology group specializing in antibody-based therapies for cancer and other serious diseases, reported recent activity under its ongoing share buy-back program. The company, which has a 25-year track record advancing bispecific antibodies, ADCs and other next-generation formats and now supports eight approved antibody medicines, continues to invest in its late-stage clinical pipeline across North America, Europe and Asia-Pacific.

In a company announcement dated March 2, 2026, Genmab disclosed that between February 23 and February 27, 2026 it repurchased a total of 85,000 shares under its previously announced buy-back program, at average prices ranging from DKK 1,825.23 to DKK 1,856.49. These transactions lifted the accumulated value of purchases under the program to DKK 271.9 million and left Genmab holding 2,763,851 treasury shares, equal to 4.30% of its share capital and voting rights, as it executes a DKK 725 million buy-back to meet obligations under its Restricted Stock Unit program.

The program, initiated on February 17, 2026 and expected to run no later than March 31, 2026, is conducted under the EU Market Abuse Regulation and the associated Safe Harbour framework. The growing treasury position reflects Genmab’s continued use of share repurchases to service equity-based compensation while potentially signaling confidence in its long-term value proposition to investors amid an expanding antibody therapeutics portfolio.

The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.

The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines to treat cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, the company’s technologies span bispecific antibodies, antibody–drug conjugates, immune-modulating antibodies and other next-generation formats, supporting eight approved drugs and a late-stage clinical pipeline across global markets.

Genmab operates in North America, Europe and the Asia-Pacific region, leveraging its antibody platforms to advance wholly owned and partnered programs. Its long-standing emphasis on scientific innovation and collaborations underpins its position in the global biopharmaceutical sector, where it aims to deliver transformative therapies and sustain growth in oncology and related indications.

Average Trading Volume: 1,704,331

Technical Sentiment Signal: Buy

Current Market Cap: $17.97B

For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.